PPARG and Parkinson disease: The authors suggested treatment targeting peroxisome proliferator-activated receptor gamma (PPARγ), which is responsible for the mitochondrial biogenesis pathway and has been linked to a markedly reduced risk of PD, potentially compensating for somatic mtDNA damage [77].